阿达格拉西布联合西妥昔单抗治疗KRASG12C突变转移性结直肠癌患者的疗效与安全性
KRYSTAL-1试验分析中,94例既往经治的KRASG12C突变不可切除或转移性结直肠癌患者接受阿达格拉西布(600 mg每日两次)联合西妥昔单抗治疗。中位随访11.9个月,客观缓解率为34.0%,疾病控制率85.1%,中位缓解持续时间5.8个月(95%CI 4.2-7.6),中位无进展生存期6.9个月(95%CI 5.7-7.4),中位总生存期15.9个月(95%CI 11.8-18.8)。所有患者均发生治疗相关不良事件,3-4级占27.7%,无5级事件,无治疗相关不良事件导致阿达格拉西布停药。
要点
- 阿达格拉西布联合西妥昔单抗在经治KRASG12C突变转移性结直肠癌中客观缓解率34.0%,疾病控制率85.1%。
- 中位无进展生存期6.9个月,中位总生存期15.9个月,中位缓解持续时间5.8个月。
- 所有患者发生治疗相关不良事件,3-4级占27.7%,无5级事件,无因不良事件停用阿达格拉西布。
核心结论
- 阿达格拉西布联合西妥昔单抗在重度经治的不可切除或转移性KRASG12C突变结直肠癌患者中显示出有前景的临床活性和可耐受的安全性。
- 这些数据支持其可能成为新的标准治疗,并强调在结直肠癌患者中检测和识别KRASG12C突变的重要性。
研究设计与样本
- KRYSTAL-1试验分析,既往经治的KRASG12C突变不可切除或转移性结直肠癌患者接受阿达格拉西布(600 mg每日两次)联合西妥昔单抗治疗,共94例患者接受治疗。
- 主要终点为盲法独立中心审查评估的客观缓解率。
主要发现
- 中位随访11.9个月,客观缓解率为34.0%,疾病控制率为85.1%,中位缓解持续时间为5.8个月(95%CI 4.2-7.6)。
- 中位无进展生存期为6.9个月(95%CI 5.7-7.4),中位总生存期为15.9个月(95%CI 11.8-18.8)。
- 所有患者发生治疗相关不良事件,3-4级占27.7%,无5级事件,无治疗相关不良事件导致阿达格拉西布停药。
- 探索性分析提示循环肿瘤DNA可能识别缓解和获得性耐药的特征。
临床怎么用
- 作者认为这些数据支持阿达格拉西布联合西妥昔单抗可能成为新的标准治疗,并强调在结直肠癌患者中检测和识别KRASG12C突变的重要性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Adagrasib, an irreversible, selective KRASG12C inhibitor, may be an effective treatment in KRASG12C-mutated colorectal cancer, particularly when combined with an anti-EGFR antibody. In this analysis of the KRYSTAL-1 trial, patients with previously treated KRASG12C-mutated unresectable or metastatic colorectal cancer received adagrasib (600 mg twice daily) plus cetuximab. The primary endpoint was objective response rate (ORR) by blinded independent central review. Ninety-four patients received adagrasib plus cetuximab. With a median follow-up of 11.9 months, ORR was 34.0%, disease control rate was 85.1%, and median duration of response was 5.8 months (95% confidence interval [CI], 4.2-7.6). Median progression-free survival was 6.9 months (95% CI, 5.7-7.4) and median overall survival was 15.9 months (95% CI, 11.8-18.8). Treatment-related adverse events (TRAEs) occurred in all patients; grade 3-4 in 27.7% and no grade 5. No TRAEs led to adagrasib discontinuation. Exploratory analyses suggest circulating tumor DNA may identify features of response and acquired resistance. SIGNIFICANCE: Adagrasib plus cetuximab demonstrates promising clinical activity and tolerable safety in heavily pretreated patients with unresectable or metastatic KRASG12C-mutated colorectal cancer. These data support a potential new standard of care and highlight the significance of testing and identification of KRASG12C mutations in patients with colorectal cancer. This article is featured in Selected Articles from This Issue, p. 897.
引用
- Yaeger R, Uboha NV, Pelster MS, et al. Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer. Cancer Discov. 2024. PMID: 38587856. doi:10.1158/2159-8290.CD-24-0217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。